A Reliable Tool for Detecting 7-Dehydrocholesterol and Cholesterol in Human Plasma and Its Use in Diagnosis of Smith-Lemli-Opitz Syndrome

Yitao Luo,Zhengyuan Liu,Yujie Zeng,Yuxiao Zhang,Yujing Luan,Li Ma,Li Chen,Lin Zou,Jingmin Yang,Zhibin Huang,Yulan Rao,Chengqiang Zhang
DOI: https://doi.org/10.1002/jssc.202100594
IF: 3.614
2022-01-01
Journal of Separation Science
Abstract:Background Smith-Lemli-Opitz syndrome is a birth defect caused by the deficiency of 7-dehydrocholesterol reductase in cholesterol biosynthesis pathway, which leads to accumulation of 7-dehydrocholesterol and reduction of cholesterol in body fluids. To effectively diagnose Smith-Lemli-Opitz syndrome and monitor therapy, a reliable method for simultaneous detection of 7-dehydrocholesterol and cholesterol is needed. Methods In the presence of antioxidants (2,6-ditert-butyl-4-methylphenol and triphenylphosphine), 50 mu L of human plasma were hydrolyzed at 70celcius for 40 min with 1 M potassium hydroxide in 90% ethanol, and then 7-dehydrocholesterol and cholesterol were extracted by 600 mu L of n-hexane for three times. After microwave-assisted derivatization with 70 mu L of N,O-bis(trimethylsilyl)trifluoroacetamide at 460 W for 3 min, the analytes were measured by gas chromatography-mass spectrometry. Results The limits of detection were 100 ng/mL for 7-dehydrocholesterol and 300 ng/mL for cholesterol. Good linearity was obtained in the range of 1-600 mu g/mL for 7-dehydrocholesterol and 10-600 mu g/mL for cholesterol, which completely covered the biochemical levels of Smith-Lemli-Opitz syndrome patients that have been reported. Conclusion A time-saving and accurate gas chromatography with mass spectrometry based method was developed for the determination of 7-dehydrocholesterol and cholesterol in human plasma, which also serves as a useful tool for Smith-Lemli-Opitz syndrome diagnosis, treatment, and research.
What problem does this paper attempt to address?